HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $24 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Coherus BioSciences (NASDAQ:CHRS) and maintains a $24 price target.
June 01, 2023 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao reiterates a Buy rating on Coherus BioSciences and maintains a $24 price target.
The news directly mentions Coherus BioSciences (CHRS) and the analyst's Buy rating and maintained price target of $24. This positive rating from a reputable analyst is likely to have a positive short-term impact on the stock price, as it signals confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100